Surgery Partners Inc (SGRY) Stock Forecast & Price Target
Surgery Partners Inc · NASDAQ
$15.57+0.40 (+2.64%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Surgery Partners Inc, 6 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $14.00 to $36.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $22.25 sits 43% above the current $15.57. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.13 next quarter toward $0.67 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy675%
Hold225%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Surgery Partners Inc.
As of Jul, 6 of 8 firms rate SGRY a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SGRY EPS & revenue forecast
EPS · NEXT QUARTER
$0.13
Range $0.06 – $0.20 · 10 analysts · +2% YoY
Next period, 10 analysts expect Surgery Partners Inc to earn $0.13 a share (range $0.06 – $0.20), versus $0.13 a year earlier. Full-year consensus is $0.46, growing to $0.67 the year after.
REVENUE · NEXT QUARTER
$849.7M
Range $839.4M – $859.0M · 10 analysts · +3% YoY
Revenue is expected to reach $849.7M (range $839.4M – $859.0M), +3.4% year-over-year. Full-year consensus is $3.4B, rising to $3.6B next year.
Top analysts covering Surgery Partners Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SGRY.
#1
BS
Bill Sutherland
Benchmark · Rank #52
Buy
$24.00+54.1% to target
Overall win rate
44%
+ Follow
#2
Tao Qiu
Macquarie · Rank #112
Buy
$33.00+111.9% to target
Overall win rate
42%
+ Follow
#3
Ben Hendrix
RBC Capital · Rank #117
Buy
$20.00+28.5% to target
Overall win rate
44%
+ Follow
#4
Sarah James
Cantor Fitzgerald
Buy
$33.00+111.9% to target
Coverage
—
+ Follow
#5
AR
A.J. Rice
UBS
Buy
$21.00+34.9% to target
Coverage
—
+ Follow
SGRY stock forecast FAQ
What is SGRY's average 12-month price target?+
The 8 analysts with a live target average $22.25 for Surgery Partners Inc over the next 12 months, ranging from a $36.00 high to a $14.00 low.
Is SGRY stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 6 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SGRY?+
The Street-high target is $36.00 (Cantor Fitzgerald), and the Street-low is $14.00 (Barclays). The average of all 8 active targets is $22.25.
How many Wall Street analysts cover SGRY?+
8 analysts have an active rating on Surgery Partners Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering SGRY?+
Among analysts who currently cover SGRY, Bill Sutherland of Benchmark has the strongest overall Quantellect track record (Rank #52). Their current call is Buy with a $24.00 target.
What is Surgery Partners Inc's projected EPS for next quarter?+
The consensus estimate is $0.13 per share (range $0.06 – $0.20) across 10 analysts. Full-year EPS is projected at $0.46, rising to $0.67 the following year.
How much revenue is Surgery Partners Inc expected to report next quarter?+
Consensus revenue is $849.7M (range $839.4M – $859.0M). Full-year revenue is projected at $3.4B, growing to $3.6B next year.
Have analysts been upgrading or downgrading SGRY lately?+
As of Jul, 6 of 8 firms rate SGRY a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SGRY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
